Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers

Segovia, Alcira Mercedes; Russo, Sofia; Girotti, Maria RominaIcon ; Rabinovich, Gabriel AdriánIcon ; Hill, Marcelo
Fecha de publicación: 03/2020
Editorial: Wiley Blackwell Publishing, Inc
Revista: Clinical and Experimental Immunology
ISSN: 0009-9104
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Inmunología

Resumen

Immune checkpoint blockers improve the overall survival of a limitednumber of patients among different cancers. Identifying pathways thatinfluence the immunological and clinical response to treatment is criticalto improve the therapeutic efficacy and predict clinical responses. Recently,a key role has been assigned to innate immune mechanisms in checkpointblockade-driven anti-tumor responses. However, inflammatory pathwayscan both improve and impair anti-tumor immunity. In this review, wediscuss how different inflammatory pathways, particularly inflammasomeactivation, can influence the clinical outcome of immune checkpoint blockers.Inflammasome activation may reinforce anti-tumor immunity by boostingCD8+ T cell priming as well as by enhancing T helper type 17 (Th17)responses. In particular, we focus on the modulation of the cation channeltransmembrane protein 176B (TMEM176B) and the ectonucleotidase CD39as potential targets to unleash inflammasome activation leading to reinforcedanti-tumor immunity and improved efficacy of immune checkpointblockers. Future studies should be aimed at investigating the mechanismsand cell subsets involved in inflammasome-driven anti-tumor responses.
Palabras clave: INFLAMMOSOME , IMMUNE CHECKPOINT BLOCKERS , TMEM176B , CANCER IMMUNOTHERAPY
Ver el registro completo
 
Archivos asociados
Tamaño: 263.2Kb
Formato: PDF
.
Solicitar
Licencia
info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/143989
URL: https://onlinelibrary.wiley.com/doi/full/10.1111/cei.13433
URL: https://doi.org/10.1111/cei.13433
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Segovia, Alcira Mercedes; Russo, Sofia; Girotti, Maria Romina; Rabinovich, Gabriel Adrián; Hill, Marcelo; Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 200; 2; 3-2020; 155-162
Compartir
Estadísticas
Visualizaciones: 40
Descargas: 0

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • Sound Cloud

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

Ministerio
https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES